Poor Efficacy of Immune Checkpoint Inhibitors Plus Chemotherapy in Lung Cancer Patients with EGFR/ERBB2 Exon 20 Insertion

医学 化疗 贝伐单抗 肺癌 内科学 肿瘤科 免疫疗法 癌症
作者
Yue Zheng,Yang Fu,Yueyun Chen,Qing Li,Ting Liu,Zhenyu Ding
出处
期刊:Current Oncology [Multidisciplinary Digital Publishing Institute]
卷期号:30 (11): 9929-9939 被引量:1
标识
DOI:10.3390/curroncol30110721
摘要

Background: EGFR and ERBB2 exon 20 insertion (Ex20ins) account for a small fraction of patients with EGFR mutations. The efficacy of immune checkpoint inhibitors (ICIs) for these patients was still controversial. Methods: This retrospective study enrolled lung cancer patients harboring either EGFR or ERBB2 Ex20ins mutations. All the patients were treated with platinum-based chemotherapy plus ICIs, or platinum-based chemotherapy. The demographic features and clinical outcome of each patient were reviewed and analyzed. Results: When treated with immunochemotherapy, patients with EGFR/ERBB2 Ex20ins mutations (n = 31) had poor PFS compared with those without EGFR mutations (n = 141, 5.0 mon and 11.2 mon, p < 0.001). When compared with those with EGFR classic mutations who received immunotherapy as the salvage therapy (n = 24), these patients with EGFR/ERBB2 Ex20ins mutations had similar PFS (5.0 mon and 4.1 mon, p = 0.625), ORR (37.5% vs. 48.4%), and DCR (70.8% vs. 77.4%). In the patients with EGFR/ERBB2 Ex20ins mutations, the PFS of those treated with chemotherapy (n = 54) and those treated with immunochemotherapy (n = 31) was 6.5 mon vs. 5.0 mon (p = 0.066). In the EGFR Ex20ins subgroup, the PFS of addition of bevacizumab to chemotherapy (n = 20) and chemotherapy alone (n = 16) was 8.8 mon and 5.2 mon, respectively (p = 0.082) or immunochemotherapy (n = 15, 8.8 mon and 5.0 mon, p = 0.097). Similarly, in the ERBB2 subgroup, the combination of bevacizumab and chemotherapy achieved a numerically longer PFS over chemotherapy alone (9.1 mon and 4.5 mon, p = 0.253), but there was no statistical significance. Conclusions: This study showed that platinum-based chemotherapy plus ICIs had limited efficiency compared to platinum-based chemotherapy for patients with EGFR/ERBB2 Ex20ins. Chemotherapy plus bevacizumab may be a potential scheme for these patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
尘埃之影完成签到,获得积分10
1秒前
陶醉的钢笔完成签到 ,获得积分10
2秒前
飞行的子弹完成签到,获得积分20
3秒前
泥花完成签到,获得积分10
3秒前
3秒前
mr_beard完成签到 ,获得积分10
4秒前
岑晓冰完成签到 ,获得积分10
6秒前
啦啦啦完成签到,获得积分10
6秒前
感动的小鸽子完成签到 ,获得积分10
7秒前
lxj完成签到 ,获得积分10
7秒前
无辜的蜗牛完成签到 ,获得积分10
7秒前
xiaojin完成签到,获得积分10
8秒前
程程完成签到,获得积分10
8秒前
duckspy发布了新的文献求助30
8秒前
8秒前
sunyanghu369发布了新的文献求助30
13秒前
hdc12138完成签到,获得积分10
14秒前
飞龙在天完成签到,获得积分0
14秒前
狄淇儿完成签到 ,获得积分10
14秒前
吨吨完成签到,获得积分10
15秒前
小芒果完成签到,获得积分0
19秒前
20秒前
杰克李李完成签到,获得积分10
21秒前
pakiorder完成签到,获得积分20
23秒前
无心的雅霜完成签到,获得积分10
23秒前
1122完成签到,获得积分10
24秒前
王磊完成签到,获得积分10
24秒前
顺心醉蝶完成签到 ,获得积分10
24秒前
量子星尘发布了新的文献求助10
24秒前
zhao完成签到 ,获得积分10
25秒前
yuncong323发布了新的文献求助10
25秒前
gfasdjsjdsjd发布了新的文献求助30
27秒前
pan完成签到,获得积分10
27秒前
28秒前
29秒前
魔幻的妖丽完成签到 ,获得积分10
31秒前
王小凡完成签到 ,获得积分10
31秒前
32秒前
开心薯片发布了新的文献求助10
33秒前
ZXW完成签到,获得积分10
34秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038235
求助须知:如何正确求助?哪些是违规求助? 3575992
关于积分的说明 11374009
捐赠科研通 3305760
什么是DOI,文献DOI怎么找? 1819276
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022